🇺🇸 FDA
Patent

US 10633363

EPAC1 activators as HIV latency reversal agents (LRA)

granted A61PA61P31/18

Quick answer

US patent 10633363 (EPAC1 activators as HIV latency reversal agents (LRA)) held by The Board of Regents of the University of Texas System expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61P, A61P31/18